Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
Active, not recruiting · NCT05327270 · Registry updated 2026-06-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions | Head and Neck Neoplasms, Neoplasms by Site, head and neck cancer, neoplasm | Active, not recruiting | Phase 1 | 2026-06-12 | NCT05327270 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| M D Anderson Cancer Center | Houston | United States | 667 |